Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe

Major regulatory milestone achieved toward approval in the European Union; final decision from the European Commission expected in the first quarter of 2015.

Published
21 November 2014
From
AbbVie press release
AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection

AbbVie's 3D regimen (paritaprevir/ombitasvir/ritonavir plus dasabuvir) with ribavirin for 12 weeks and Gilead Science's sofosbuvir (Sovaldi) plus ribavirin for 24 weeks both produced good sustained virological response

Published
21 November 2014
By
Liz Highleyman
Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients

A 12-week oral combination of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high sustained virological response rates for people with difficult-to-treat HCV genotype 3 and other genotypes,

Published
19 November 2014
By
Liz Highleyman
NHS asks Nice to delay ground-breaking hepatitis C drug

Nice is due to finish its final assessment of sofosbuvir in January. It is usual for them to give the NHS three months to find the money or put staff – if needed – in place. NHS England is thought to have asked them to delay this by six months.

Published
19 November 2014
From
Channel 4 News (blog)
European Commission Grants Marketing Authorization for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir)

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir (LDV) with the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved by the European Commission under the tradename Sovaldi® in January 2014.

Published
19 November 2014
From
Gilead press release
Merck's grazoprevir/elbasvir combo shows high cure rates, including for people with cirrhosis and HIV/HCV co-infection

An all-oral regimen of grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without ribavirin for 12 weeks, demonstrated high sustained virological response (SVR) rates for treatment-naive and treatment-experienced

Published
13 November 2014
By
Liz Highleyman
Sofosbuvir/ledipasvir and AbbVie 3D regimen cure most people with HCV genotype 4

Sofosbuvir/ledipasvir without ribavirin and AbbVie's 3D regimen (paritaprevir/ombitasvir plus dasabuvir) both produced high sustained virological response rates for people with hepatitis C virus (HCV) genotype 4, according to

Published
13 November 2014
By
Liz Highleyman
Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis

An oral regimen of sofosbuvir/ledipasvir plus ribavirin taken for 12 weeks cured most hepatitis C patients with decompensated cirrhosis, the most advanced stage of liver disease, according to

Published
12 November 2014
By
Liz Highleyman
Daclatasvir TRIO regimen has good cure rates for hepatitis C patients with or without cirrhosis

A 12-week all-oral regimen of daclatasvir, asunaprevir and beclabuvir, with or without ribavirin, cured 86 to 90% of genotype 1 hepatitis C patients with cirrhosis in the phase

Published
11 November 2014
By
Liz Highleyman
New HCV drugs pass muster in real world

Clinical trials for some of the new direct-acting agents against hepatitis C (HCV) have yielded some impressive efficacy numbers. But how well do the drugs stack up in the real world?

Published
11 November 2014
From
MedPage Today
← First12345...52Next →

Filter by country